Applications

1452 – Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

ImmunoHistoChemistry (IHC) test for identification of Mismatch Repair Deficiency (dMMR) for access to pembrolizumab in patients with Stage IV CRC.

Type: Co-dependent technology

Medical condition this application addresses

Stage IV Colorectal Carcinoma (CRC) who are receiving first line (1L) treatment.

Meetings to consider this application

  • PASC meeting: 8 December 2016
  • ESC meeting: -
  • MSAC meeting: -